CA-BIOLYTIC-LAB
14.4.2020 19:02:07 CEST | Business Wire | Press release
Biolytic Lab Performance Inc. unveiled its novel oligo synthesizer, the Dr. Oligo 768XLc , the most commercially advanced platform for high throughput nucleic acid synthesis. Designed to be operated in both R&D and production facilities, it fits the needs of organizations focused on diagnostic and therapeutic applications for various viruses, diseases and conditions where large quantities of unique DNA and RNA are critical to their products, services and ongoing research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200414005164/en/
Such applications include gene synthesis, genetic diagnostic test kits, PCR/RT – PCR, siRNA,/RNAi, miRNA, CRISPR Cas9, anti-sense treatments and DNA/RNA sequencing – to broader areas like evolutionary history, forensics, immunotherapy, diagnostic and therapeutic research – to high-throughput screening, modified oligos, mixed backbones, LNAs and the visual detection of virus RNA such as COVID-19 following RT-LAMP amplification with DNA primers.
Ready to Run
The Dr. Oligo 768XLc includes fully tested protocols and initial 384-well synthesis media from 2 to 100 nmol per well for turn-key synthesis beginnings. Available with optional trityl collection, oligo desalting and elution capabilities.
Efficient Reactions
B iolytic's novel patent pending system results is the highest possible chemical reaction efficiency using the minimum amount of reagents across our entire line of Dr. Oligo XLc instruments. Our system overcomes chemistry over consumption and reaction inconsistencies that are a result of well to well flow rate variability and other issues typical in high throughput synthesis media.
Features
- Extremely Efficient Mixing of all reagents dispensed into each well using our patent pending system. The entire volume of reagent delivered to each reaction well is thoroughly mixed with the synthesis media resulting in optimal use of all reagent delivered.
- Deliver only the volume of each reagent needed to obtain the optimal molar excess for achieving near 100% reaction efficiency.
- A simplified design and layout resulting in easier operation and maintenance thus lowering operational costs.
- Innovative hardware designs result in efficiencies never before achieved in high throughput oligo synthesis. This translates to lowering cost of synthesis by conserving very costly unique bases / specials when synthesizing innovative, unique oligos.
- A new, patent pending nozzle system dispenses 16 nozzles simultaneously and eliminates complexities of previously available designs. This results in reduces maintenance and operating cost as well as contributing to faster synthesis time.
- Powerful Production Software providing the ability to efficiently synthesize complex molecules in high throughput while reducing consumption of costly modified nucleotide building blocks.
About Biolytic
Founded in 1993, Biolytic® Lab Performance, Inc. designs and manufactures the most advanced oligo synthesizers and related lab accessories in the world. Alongside more than 25 years of experience in end-to-end synthesis processes and equipment coupled with their extensive knowledge and customer support has allowed Biolytic to continuously lead the oligo synthesis industry.
For more information please visit www.biolytic.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005164/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom